At the JPMorgan HealthCare conference, the company disclosed Results of MariTide Chronic Weight Management Phase 2 study, stating: “The large majority of participants maintained the weight loss achieved in Part 1 for an additional 52 weeks on a lower monthly dose or quarterly dose of MariTide; The second year of MariTide treatment was very well tolerated including at quarterly doses, with a very low incidence of nausea and vomiting and no new safety signals observed; Improvements in cardiometabolic parameters were sustained with MariTide at effective maintenance doses for a full second year.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- BioMarin names Arpit Dave Chief Digital and Information Officer
- Private Markets: Anthropic raising $10B at $350B valuation
- Amgen Advances Leukemia Strategy With Completed Blinatumomab Study in Japan
- Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
- Amgen assumed at Buy from Neutral at UBS